Education Featured Article
October 03, 2012
McAfee Partners with Everloop.com to Teach Online Safety to Children
By Raju Shanbhag, TMCnet Contributor
With children getting access to Internet more than ever before, parents are increasingly concerned about their children’s safety online. It’s highly important to teach children about the ways to use the Internet responsibly.
Under this partnership, more than 50,000 school children will receive online safety messages broadcasted by McAfee volunteers, which teaches them Internet safety.
The McAfee Cares - Online Safety for Kids school initiative takes the help of volunteers to assist and train school going children about the ways to stay safe. It will also help them in maintaining acceptable online behavior.
In each session, students will receive content and materials that are based on the STOP.THINK.CONNECT national cybersecurity awareness campaign. After the assemblies on Everloop.com are over, kids can still benefit from discussions on various topics from content and resources they have learned in these sessions.
“Just as we learned to look both ways before crossing the street, we want children to learn to make smart choices when using the Internet,” said McAfee senior vice president of Global External Affairs, Michael Busselen. “Through McAfee Cares – Online Safety for Kids, we mobilize our employees to go into classrooms to teach kids about the positive steps they can take to use their digital devices safely.”
Recently, the company released some tips for parents to make sure that they take time to teach healthy online habits to their children. According to McAfee, parents can begin the New Year fresh with new resolutions that cater to their own behavior. This allows them to present themselves as an example of best practices for kids and teens.
Want to learn more about the latest in communications and technology? Then be sure to attend ITEXPO Austin 2012, happening now in Austin, TX. Stay in touch with everything happening at ITEXPO (News - Alert). Follow us on Twitter.
Edited by Braden Becker
LATEST EDUCATION NEWS
Pfizer's RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease